Levetiracetam versus Carbamazepine in Patients with Late Poststroke Seizures: A Multicenter Prospective Randomized Open-Label Study (EpIC Project)
Authors:
- D. ConsoliDCD. Consoli
- D. BoscoDBD. Bosco
- P. PostorinoPPP. Postorino
- F. GalatiFGF. Galati
- M. PlastinoMPM. Plastino
- G.F. PerticoniGPG.F. Perticoni
- G.A. OttonelloGOG.A. Ottonello
- B. PassarellaBPB. Passarella
- S. RicciSRS. Ricci
- G. NeriGNG. Neri
- D. ToniDTD. Toni
- on behalf of EPIC StudyOSon behalf of EPIC Study
Open Access
- 1 November 2012
- journal article
- research article
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 34 (4) , 282-289
Abstract
Background: Strokes are the leading cause of epileptic seizures in adults and account for 50% of seizures in those over the age of 65 years. The use of antiepileptic drugs to prevent recurrent poststroke seizures is recommended. Methods: One hundred and twenty-eight patients with poststroke seizures were randomly allocated to treatment with either levetiracetam (LEV) or sustained-release carbamazepine (CBZ) in a multicenter randomized open-label study. After a titration study phase (2 weeks), the optimal individual dose of trial medication was determined and treatment was continued for another 52 weeks. The primary endpoint was defined as the proportion of seizure-free patients; the secondary endpoints were: evaluation of time recurrence to the first seizure, EEG tracings, cognitive functions and side effects. Results: Of 128 patients, 22 discontinued the trial prematurely; thus a total of 106 patients (52 treated with LEV and 54 treated with CBZ) were included in the analysis. The results of the study were as follows: no significant difference in number of seizure-free patients between LEV and CBZ (p = 0.08); time to the first recurrence tended to be longer among patients on LEV; there was no correlation between the therapeutic effect and the EEG findings in either treatment group; LEV caused significantly fewer (p = 0.02) side effects than CBZ; attention deficit, frontal executive functions and functional scales (Activities of Daily Living and Instrumental Activities of Daily Living indices) were significantly worse in the CBZ group. Conclusions: This trial suggests that LEV may be a valid alternative to CBZ in poststroke seizures, particularly in terms of efficacy and safety. In addition, our results show that LEV has significant advantages over CBZ on cognitive functions. This trial also indicates that LEV in monotherapy is a safe and effective therapeutic option in elderly patients who have suffered epileptic seizures following a stroke.Keywords
This publication has 28 references indexed in Scilit:
- Early poststroke seizuresNeurology, 2011
- Predictors of Acute Poststroke SeizuresCerebrovascular Diseases, 2010
- The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of AgeClinical Pharmacokinetics, 2006
- Reliability and Normative Data for the Benton Visual Form Discrimination TestThe Clinical Neuropsychologist, 2003
- Drug Treatment of Epilepsy in Elderly PeopleDrugs & Aging, 2003
- Improving the Reliability of Stroke Subgroup Classification Using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) CriteriaStroke, 2001
- Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial SeizuresEpilepsia, 2000
- Composite neuropsychological batteries and demographic correction: Standardization based on equivalent scores, with a review of Published DataJournal of Clinical and Experimental Neuropsychology, 1997
- Cerebral Embolization: Prospective Clinical Analysis of 42 CasesStroke, 1971